Abstract
Purpose of reviewThe objective of this article is to review the available literature regarding the risks associated with sublingual immunotherapy and angiotensin-converting enzyme (ACE) inhibitors or β-blocker use. It also evaluates for any differences in these risks among the available sublingual immunotherapy (SLIT) tablets.Recent findingsA literature search was conducted in PubMed to identify peer-reviewed articles using the following keywords: anaphylaxis, ACE inhibitor, β-blocker, and sublingual immunotherapy. Minimal data exist regarding their safety of SLIT in patients concomitantly taking ACE inhibitors or β-blockers. The adverse reaction rates seem similar between SLIT products.SummaryA risk-versus-benefit discussion should be communicated with the patient taking a β-blocker before beginning SLIT but automatic denial of SLIT to these patients is not warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 401-406 |
| Number of pages | 6 |
| Journal | Current opinion in allergy and clinical immunology |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Aug 2020 |
Keywords
- anaphylaxis
- angiotensin-converting enzyme inhibitor
- sublingual immunotherapy
- β-blocker
Fingerprint
Dive into the research topics of 'β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: Are risks related to individual product safety profile?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver